Cystic fibrosis: Investigational therapies
- Richard H Simon, MD
Richard H Simon, MD
- Professor of Medicine
- University of Michigan Health Sciences Center
- Thomas H Sisson, MD
Thomas H Sisson, MD
- Professor of Medicine
- University of Michigan
The survival rate of patients with cystic fibrosis (CF) continues to improve. In 1985, the median predicted survival was 25 years of age, while in 2016 it had increased to 42 years . In an effort to further prolong the life span of patients with CF, many potential new treatments are being actively investigated. This topic review will summarize some of the promising experimental therapies that have advanced to clinical trials. They include approaches to replace the abnormal Cystic fibrosis transmembrane conductance regulator (CFTR) gene, reverse the consequences of the genetic defect on protein function, promote clearance of respiratory secretions, reduce or eliminate bacterial infection, and reduce the deleterious pulmonary inflammatory response. Those trials that are listed in the NIH Clinical Trials Registry will be designated by including their NCT identifier codes, and further details about each trial are available through links to that database.
The drive for developing gene therapy to treat CF began in earnest in 1989 with the identification and cloning of the Cystic fibrosis transmembrane conductance regulator (CFTR) gene. Because mutations in CFTR account for virtually all cases of CF, correcting abnormalities in this single gene should theoretically cure the disease (see "Cystic fibrosis: Genetics and pathogenesis"). Despite early progress in the gene therapy field, many significant obstacles impede the development of this approach as a treatment for CF including vector efficiency, transgene persistence, and evasion of host immune responses. To overcome these barriers, research in this field is focusing on developing more efficient and safe vectors [2,3].
The UK Cystic Fibrosis Gene Therapy Consortium has tested a cationic lipid formulation (GL67A) to transfer a cytosine-phosphate-guanine (CpG)-free plasmid encoding functional human CFTR cDNA to the airway epithelium (where CpG-free refers to plasmids lacking a specific DNA sequence known to induce inflammation in experimental animals) . Twelve monthly administrations of the lipid/plasmid formulation resulted in prolonged CFTR gene expression (>140 days) in the lungs of mice, with minimal toxicity . The results of a randomized, double-blind, phase 2b clinical trial in CF subjects have been reported . Participants with CF received a CFTR-containing plasmid in GL67A or placebo every 4 weeks for 48 weeks, and the primary endpoint was the relative change in percent predicted forced expiratory volume in one second (FEV1). A subgroup also received intranasal administrations so that nasal transepithelial potential difference could be tested to directly assess for successful expression of the CFTR channel. Subjects who received the CFTR-GL67A formulation demonstrated a modest 3.7 percent increase in percent predicted FEV1 at week 48 compared with the placebo group (95% CI 0.1%–7.3%; p = 0.046). The CFTR-GL67A-treated patients also had improvement in several secondary endpoints including forced vital capacity (FVC) and a CT measurement of gas trapping (p = 0.048). However, other secondary endpoints including quality of life were not different between the two groups. A subset of patients underwent bronchoscopy to evaluate CFTR gene expression. Vector-specific DNA was detected in 12 of 14 CFTR-GL67A-treated patients and was below the limit of measurement in all (n = 7) placebo samples (p = 0.00); however, there was no vector-specific mRNA detected in bronchial samples from either group. Nasal potential difference measurements did not change significantly during the study. In summary, these results indicate that substantial improvements to this approach will need to be made for it to move forward in the treatment of CF lung disease.
Preclinical work is progressing on the development of lentivirus-based  and adeno-associated virus-based  vectors for CFTR gene transfer to airway epithelium. Advancements in gene editing technology hold promise, but applications of techniques such as CRISPR/Cas to CF are in only very early stages of development .
REVERSING THE CONSEQUENCES OF CFTR MUTATIONS ON PROTEIN FUNCTION
Ivacaftor, a small molecular weight compound developed to treat CFTR class III (gating) mutations, was the first mutation-specific drug to receive Food and Drug Administration (FDA) approval for use in CF. This drug was initially approved for treatment of patients with the G551D gating defect and was then expanded to eight other gating mutations (G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R). As of May 2017, the list was further expanded, so that ivacaftor is approved by the FDA for the treatment of 33 CFTR mutations (table 1)  Although the approval of ivacaftor represented a remarkable advance, these gating and residual function mutations are present in only approximately 10 percent of CF patients. (See "Cystic fibrosis: Overview of the treatment of lung disease", section on 'Ivacaftor for G551D, other gating mutations, and residual function mutations'.)To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:
- Cystic Fibrosis Foundation Patient Registry 2015 Annual Data Report. Bethesda, Maryland. Available at: https://www.cff.org/Research/Researcher-Resources/Patient-Registry/ (Accessed on April 14, 2017).
- Prickett M, Jain M. Gene therapy in cystic fibrosis. Transl Res 2013; 161:255.
- Griesenbach U, Alton EW. Progress in gene and cell therapy for cystic fibrosis lung disease. Curr Pharm Des 2012; 18:642.
- Alton EW, Boyd AC, Cheng SH, et al. Toxicology study assessing efficacy and safety of repeated administration of lipid/DNA complexes to mouse lung. Gene Ther 2014; 21:89.
- Alton EW, Armstrong DK, Ashby D, et al. Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med 2015; 3:684.
- Griesenbach U, Inoue M, Meng C, et al. Assessment of F/HN-pseudotyped lentivirus as a clinically relevant vector for lung gene therapy. Am J Respir Crit Care Med 2012; 186:846.
- Keswani SG, Balaji S, Le L, et al. Pseudotyped AAV vector-mediated gene transfer in a human fetal trachea xenograft model: implications for in utero gene therapy for cystic fibrosis. PLoS One 2012; 7:e43633.
- Firth AL, Menon T, Parker GS, et al. Functional Gene Correction for Cystic Fibrosis in Lung Epithelial Cells Generated from Patient iPSCs. Cell Rep 2015; 12:1385.
- Kalydeco prescribing information, revised 5/2017. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203188s019lbl.pdf (Accessed on June 01, 2017).
- Rowe S, Sermet-Gaudelus I, Konstan M, et al. Results of the phase 3 study of ataluren in nonsense mutation cystic fibrosis (NMCF) [Abstract 193]. Pediatr Pulmonol 2012; 47:290.
- Kerem E, Konstan MW, De Boeck K, et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med 2014; 2:539.
- PTC therapeutics press release, 3/2/17. PTC Therapeutics Announces Results from Pivotal Phase 3 Clinical Trial of Ataluren in Patients Living with Nonsense Mutation Cystic Fibrosis. Available at: http://ir.ptcbio.com/releasedetail.cfm?releaseid=1015471 (Accessed on May 18, 2017).
- PTC Therapeutics press release 3/16/17: PTC Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update. Available at: http://ir.ptcbio.com/releasedetail.cfm?releaseid=1017651 (Accessed on May 18, 2017).
- Thomas PJ, Ko YH, Pedersen PL. Altered protein folding may be the molecular basis of most cases of cystic fibrosis. FEBS Lett 1992; 312:7.
- Van Goor F, Hadida S, Grootenhuis PD, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci U S A 2011; 108:18843.
- Jennings MT, Dezube R, Paranjape S, et al. An Observational Study of Outcomes and Tolerances in Patients with Cystic Fibrosis Initiated on Lumacaftor/Ivacaftor. Ann Am Thorac Soc 2017.
- Vertex Phamaceuticals press release 3/28/17: Two Phase 3 Studies of the Tezacaftor/Ivacaftor Combination Treatment Met Primary Endpoints with Statistically Significant Improvements in Lung Function (FEV1) in People with Cystic Fibrosis. Available at: http://investors.vrtx.com/releasedetail.cfm?ReleaseID=1019156 (Accessed on May 18, 2017).
- Vertex Pharmaceuticals press release 8/15/16: Vertex Provides Update on Ongoing Phase 3 Program for VX-661 in Combination with Ivacaftor for the Treatment of Cystic Fibrosis. Available at: http://investors.vrtx.com/releasedetail.cfm?ReleaseID=984388 (Accessed on May 18, 2017).
- Bilton D, Robinson P, Cooper P, et al. Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study. Eur Respir J 2011; 38:1071.
- Aitken ML, Bellon G, De Boeck K, et al. Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study. Am J Respir Crit Care Med 2012; 185:645.
- Trapnell BC, McColley SA, Kissner DG, et al. Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection. Am J Respir Crit Care Med 2012; 185:171.
- Minutes from the Pulmonary-Allergy Drugs Advisory Committee (PADAC) of the Center for Drug Evaluation and Research, January 30, 2013. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM340156.pdf (Accessed on July 10, 2013).
- Minasian C, Wallis C, Metcalfe C, Bush A. Comparison of inhaled mannitol, daily rhDNase and a combination of both in children with cystic fibrosis: a randomised trial. Thorax 2010; 65:51.
- Quinton PM. Cystic fibrosis: impaired bicarbonate secretion and mucoviscidosis. Lancet 2008; 372:415.
- Elborn JS, Geller D, Conrad D, et al. Phase 3 trial of inhaled levofloxacin (Aeroquin™, MP-376, APT-1026) vs. tobramycin inhalation solution (TIS) in intensively treated CF patients over 6 months. J Cyst Fibros 2013; 12:S35.
- Stuart Elborn J, Geller DE, Conrad D, et al. A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients. J Cyst Fibros 2015; 14:507.
- Schuster A, Haliburn C, Döring G, et al. Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study. Thorax 2013; 68:344.
- Deppisch C, Herrmann G, Graepler-Mainka U, et al. Gaseous nitric oxide to treat antibiotic resistant bacterial and fungal lung infections in patients with cystic fibrosis: a phase I clinical study. Infection 2016; 44:513.
- Muhlebach MS, Beckett V, Popowitch E, et al. Microbiological efficacy of early MRSA treatment in cystic fibrosis in a randomised controlled trial. Thorax 2017; 72:318.
- Nichols DP, Konstan MW, Chmiel JF. Anti-inflammatory therapies for cystic fibrosis-related lung disease. Clin Rev Allergy Immunol 2008; 35:135.
- Rahman I, MacNee W. Oxidative stress and regulation of glutathione in lung inflammation. Eur Respir J 2000; 16:534.
- Dauletbaev N, Fischer P, Aulbach B, et al. A phase II study on safety and efficacy of high-dose N-acetylcysteine in patients with cystic fibrosis. Eur J Med Res 2009; 14:352.
- Griese M, Kappler M, Eismann C, et al. Inhalation treatment with glutathione in patients with cystic fibrosis. A randomized clinical trial. Am J Respir Crit Care Med 2013; 188:83.
- Visca A, Bishop CT, Hilton S, Hudson VM. Oral reduced L-glutathione improves growth in pediatric cystic fibrosis patients. J Pediatr Gastroenterol Nutr 2015; 60:802.
- Poschet JF, Timmins GS, Taylor-Cousar JL, et al. Pharmacological modulation of cGMP levels by phosphodiesterase 5 inhibitors as a therapeutic strategy for treatment of respiratory pathology in cystic fibrosis. Am J Physiol Lung Cell Mol Physiol 2007; 293:L712.
- Corbus pharmaceuticals press release 3/30/17. orbus Reports Positive Topline Data Demonstrating Anabasum Reduces Acute Pulmonary Exacerbations and Multiple Inflammatory Biomarkers in Phase 2 Study in Patients with Cystic Fibrosis. Available at: http://www.corbuspharma.com/news/press-releases/ (Accessed on May 18, 2017).
- GENE THERAPY
- REVERSING THE CONSEQUENCES OF CFTR MUTATIONS ON PROTEIN FUNCTION
- Class I mutations: Defective protein production
- Class II mutations: Defective protein processing
- - Lumacaftor-ivacaftor
- - Tezacaftor-ivacaftor
- - Additional compounds with f508del corrector properties
- - Add-on CFTR correctors
- Class III mutations: Defective regulation
- Class IV mutations: Defective channels
- - Mutiple class independent CFTR correctors
- CORRECTING ION FLUX ABNORMALITIES BY NON-CFTR TARGETED APPROACHES
- INHALED AGENTS TO RECONSTITUTE THE NORMAL AIRWAY SURFACE ENVIRONMENT
- ANTIBIOTICS AND ANTI-INFECTIVES
- Inhaled antibiotics
- Intravenous antibiotics
- Antibiotic treatment for eradication of MRSA
- Antipseudomonas antibody treatment
- ANTIINFLAMMATORY THERAPY
- SOCIETY GUIDELINE LINKS
- INFORMATION FOR PATIENTS